Melanoma: Workup and Surveillance

Clinics in Plastic Surgery

Volumn 37, Issue 1, 2010, Pages 55-63

  Lifchez, Scott D ^a   Kelamis, J Alex ^b  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Melanoma; Recurrence; Sentinel lymph node; Staging; Surveillance

Indexed keywords

MELAN A; MONOPHENOL MONOOXYGENASE;

ANAMNESIS; BONE METASTASIS; BRAIN METASTASIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DISEASE SURVEILLANCE; ECHOGRAPHY; GASTROINTESTINAL SURGERY; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN SURGERY; THORAX RADIOGRAPHY; VISCERAL METASTASIS;

HUMANS; MELANOMA; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 70449432829     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2009.08.004     Document Type: Review

References (48)

1. McHugh J.B., Su L., Griffith K.A., et al. Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol 13 9 (2006) 1216-1223
2. Leong S.P., Morita E.R., Südmeyer M., et al. Heterogeneous patterns of lymphatic drainage to sentinel lymph nodes by primary melanoma from different anatomic sites. Clin Nucl Med 30 3 (2005) 150-158
3. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 16 (2001) 3635-3648
4. Clark Jr. W.H., From L., Bernardino E.A., et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29 3 (1969) 705-727
5. Kim C.J., Reintgen D.S., and Balch C.M. The new melanoma staging system. Cancer Control 9 1 (2002) 9-15
6. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 16 (2001) 3622-3634
7. Wang T.S., Johnson T.M., Cascade P.N., et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 51 3 (2004) 399-405
8. Hofmann U., Szedlak M., Rittgen W., et al. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs, and patient survival. Br J Cancer 87 2 (2002) 151-157
9. Gimotty P.A., Elder D.E., Fraker D.L., et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 25 9 (2007) 1129-1134
10. Bedrosian I., Farjes M.B., Guerry IV D., et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1mm) with vertical growth phase. Ann Surg Oncol 7 4 (2000) 262-267
11. Ranieri J.M., Wagner J.D., Wenck S., et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 13 7 (2006) 927-932
12. McMasters K.M., Reintgen D.S., Ross M.I., et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 19 11 (2001) 2851-2855
13. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17 3 (1999) 976-983
14. Zogakis T.G., Essner R., Wang H.J., et al. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol 14 5 (2007) 1604-1611
15. Wong S.L., Morton D.L., Thompson J.F., et al. Melanoma patients with positive sentinel lymph nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 13 6 (2006) 809-816
16. Brennick J.B., and Yan S. False-positive cells in sentinel lymph nodes. Semin Diagn Pathol 25 2 (2008) 116-119
17. Thomas J.M. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 5 1 (2008) 18-23
18. Gutzmer R., Satzger I., Thoms K.M., et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4mm) melanomas. J Dtsch Dermatol Ges 6 3 (2008) 198-203
19. Cecchi R., Buralli L., Innocenti S., et al. Sentinel lymph node biopsy in patients with thick (=4mm) melanoma: a single-centre experience. J Eur Acad Dermatol Venereol 21 6 (2007) 758-761
20. Jacobs I.A., Chang C.K., and Salti G.I. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg 70 1 (2004) 59-62
21. Dalle S., Paulin C., Lapras V., et al. Fine-needle aspiration biopsy with ultrasound guidance in patients with malignant melanoma and palpable lymph nodes. Br J Dermatol 155 3 (2006) 552-556
22. Jaffer S., and Zakowski M. Fine-needle aspiration biopsy of axillary lymph nodes. Diagn Cytopathol 26 2 (2002) 69-74
23. Voit C., Schoengen A., Schwürzer-Voit M., et al. The role of ultrasound in detection and management of regional disease in melanoma patients. Semin Oncol 29 4 (2002) 353-360
24. Sabel M.S., Griffith K.A., Arora A., et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery 141 6 (2007) 728-735
25. Serpell J.W., Carne P.W., and Bailey M. Radical lymph node dissection for melanoma. ANZ J Surg 73 5 (2003) 294-299
26. Roaten J.B., Pearlman N., Gonzalez R., et al. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg 140 1 (2005) 85-89
27. Tsao H., Feldman M., Fullerton J.E., et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 140 1 (2004) 67-70
28. Miranda E.P., Gertner M., Wall J., et al. Routine imaging of asymptomatic patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 139 8 (2004) 831-836
29. Veit-Haibach P., Vogt F.M., Jablonka R., et al. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging 36 6 (2009) 910-918
30. Singh B., Ezziddin S., Palmedo H., et al. Preoperative 18FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res 18 5 (2008) 346-352
31. Voit C., Kron M., Rademaker J., et al. Molecular staging in stage II and stage III melanoma patients and its effect on long-term survival. J Clin Oncol 23 6 (2005) 1218-1227
32. Koyanagi K., Kuo C., Nakagawa T., et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 51 6 (2005) 981-988
33. Max N., Willhauck M., Wolf K., et al. Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR. Melanoma Res 11 4 (2001) 371-378
34. Scoggins C.R., Ross M.I., Reintgen D.S., et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 24 18 (2006) 2849-2857
35. Essner R., Lee J.H., Wanek L.A., et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139 9 (2004) 961-966
36. ESMO Guidelines Working Group, and Jost L. Cutaneous malignant melanoma: European Society for Medical Oncology clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 18 Suppl 2 (2007) ii71-ii73
37. Huang C.L., Provost N., Marghoob A.A., et al. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 39 3 (1998) 451-463
38. Christianson D.F., and Anderson C.M. Close monitoring and lifetime follow-up are optimal for patients with a history of melanoma. Semin Oncol 30 3 (2003) 369-374
39. Mooney M.M., Mettlin C., Michalek A.M., et al. Life-long screening of patients with intermediate thickness melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 80 6 (1997) 1052-1064
40. Poo-Hwu W.J., Ariyan S., Lamb L., et al. Follow-up recommendations for patients with American Joint Commission on Cancer stages I-III malignant melanoma. Cancer 86 (1999) 2252-2258
41. Garbe C., Paul A., Kohler-Spath H., et al. Prospective evaluations of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 21 (2003) 520-529
42. Weiss M., Loprinzi C.L., Creagan E.T., et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 274 (1995) 1703-1705
43. Rhodes A.R. Cutaneous melanoma and intervention strategies to reduce tumor-related mortality: what we know, what we don't know, and what we think we know that isn't so. Dermatol Ther 19 (2006) 50-69
44. Choi E.A., and Gershenwald J.E. Imaging studies in patients with melanomas. Surg Oncol Clin N Am 16 2 (2007) 403-430
45. Morton R.L., Craig J.C., and Thompson J.F. The role of surveillance chest x-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 16 (2009) 571-577
46. Chalmers N., and Best J.J. The significance of pulmonary nodules detected by CT but not by chest radiography in tumor staging. Clin Radiol 41 (1991) 410-412
47. Ricaniadis N., Konstadoulakis M.M., Walsh D., et al. Gastrointestinal metastases from malignant melanoma. Surg Oncol 4 (1995) 105-111
48. Meyers M.O., and Yeh J.J. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 16 4 (2009) 941-947